In contrast to the high number of reports in various hematologic and solid tumors including cutaneous melanoma, only one in vitro study has evaluated Bcl-2 targeting in uveal melanoma cells, showing synergistic effect with chemotherapy and multi-drug resistance reversion [28]. The gene discussed is BCL2; the disease is cutaneous melanoma.